Search
forLearn
5 / 801 resultslearn Tremella
learn taurine
learn Trifolium pratense
learn triticum vulgare
Research
5 / 87 results
research New effects of caffeine on corticotropin‐releasing hormone (CRH)‐induced stress along the intrafollicular classical hypothalamic–pituitary–adrenal (HPA) axis (CRH‐R1/2, IP3‐R, ACTH, MC‐R2) and the neurogenic non‐HPA axis (substance P, p75NTRand TrkA) inex vivohuman male androgenetic scalp hair follicles
Caffeine may help reduce stress-induced hair loss.
research Optogenetically Controlled TrkA Activity Improves the Regenerative Capacity of Hair‐Follicle‐Derived Stem Cells to Differentiate into Neurons and Glia
Blue-light activation of TrkA improves hair-follicle stem cells' ability to become neurons and glial cells.
research Effects of the selective TrkA agonist gambogic amide on pigmentation and growth of human hair follicles in vitro
Gambogic Amide helps maintain hair color and promotes hair growth.
research Probing the Effects of Stress Mediators on the Human Hair Follicle
Stress-related substance P may lead to hair loss and negatively affect hair growth.
research Epithelial growth control by neurotrophins: leads and lessons from the hair follicle
Neurotrophins are important for hair growth and could help treat hair loss.
Community Join
5 / 1000+ resultscommunity I built a tracker for every hair loss treatment in clinical development
A user created a tracker for hair loss treatments in clinical development, including compounds like Dermaliq, RU58841, and Pyrilutamide. The tracker updates with new information and allows filtering by conditions like androgenetic alopecia (AGA) and alopecia areata (AA).
community Traya users please help
The conversation is about seeking user experiences with Traya for hair loss treatment, focusing on the effectiveness and convenience of its doctor, diet, and product approach. The user is conducting research and requests feedback on what worked or didn't work.
community Update on PP405 Trails - Pelage
The conversation discusses interest in participating in PP405 trials for hair loss treatment, with users expressing uncertainty about eligibility due to location. Participants are eager for updates and willing to pay for shipping if trials are limited to America.
community Kintor KX -826 Pyrilutamide Adds 1 Year Phase 3 Trial For Safety
KX-826/pyrilutamide is undergoing an additional one-year safety and efficacy trial in China after a six-month study. Some participants speculate on the reasons for the extended trial and discuss the potential of other treatments.
community Kintor Pharma Announces Completion of Subject Enrollment and Dosing in Phase I Clinical Trial of AR-PROTAC(GT20029) in the US_Kintor Pharmaceutical Limited
Kintor Pharma finished enrolling and dosing participants in a Phase I trial for a hair loss treatment called AR-PROTAC (GT20029). The effectiveness of another drug, pyrilutamide (KX-826), for hair loss will be clearer after a Phase 2 trial expected to complete in January 2023.